EUVIMEDEUVIMED entdecken
Crossref

Comparative Analysis of the Effectiveness of Methotrexate Co-Administration with Baricitinib in Rheumatoid Arthritis Treatment

Kenya Terabe iD, Shuji Asai, Yutaka Yoshioka, Takefumi Kato, Toshihisa Kojima, Tomonori Kobayakawa, Tatsuo Watanabe, Yasumori Sobue, Tsuyoshi Nishiume, Mihoko Kato, Takayoshi Fujibayashi, Yuji Hirano und 8 weitere

Modern Rheumatology · 18.11.2026

DOI: 10.1093/mr/roag099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, online erschienen am 18.11.2026. Verfasst von Kenya Terabe und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the effect of methotrexate (MTX) co-administration with baricitinib (BAR) in rheumatoid arthritis (RA) treatment using a multicenter registry.

Methods

A total of 296 patients with RA treated with BAR were included (167 with MTX and 129 without MTX). Treatment effectiveness over 52 weeks was evaluated using propensity score–based overlap weighting to adjust for baseline differences. Group-based trajectory modeling (GBTM) was applied to identify distinct longitudinal response patterns.

Results

After overlap weighting, baseline characteristics were successfully balanced between groups (standardized mean differences <0.1). No significant differences were observed between the −MTX and +MTX groups in treatment retention (76.3% vs. 83.7%, p=0.213), CDAI scores at week 52 (5.7 [95% CI 4.2–7.1] vs. 5.8 [95% CI 4.5–7.1], p=0.90), or remission rates (32.1% vs. 34.5%, p=0.70). GBTM identified four distinct trajectories of disease activity; however, the distribution of MTX use did not differ across trajectory groups.

Conclusions

After adjustment for baseline differences, MTX co-administration was not associated with improved clinical outcomes or response trajectories during BAR therapy. These findings may inform treatment decisions for patients unable to receive concomitant MTX.

Schlagwörter

Stichwörter der Autor:innen

BaricitinibGroup-Based Trajectory ModelingMethotrexateOverlap WeightingReal-World DataRheumatoid Arthritis

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Rheumatology, Chitahanto Medical Center, Handa, Japan.
  • Kato Orthopaedic Clinic, Okazaki, Japan.
  • Department of Orthopaedic Surgery and Rheumatology, National Hospital Organization Nagoya Medical Centre, Nagoya, Japan.
  • Kobayakawa Orthopaedic and Rheumatologic Clinic, Fukuroi, Japan.
  • Department of Orthopaedic Surgery, Daido Hospital, Nagoya, Japan.

ORCID-Profile: Kenya Terabe

Zitieren

APA

Terabe, K., Asai, S., Yoshioka, Y., Kato, T., Kojima, T., Kobayakawa, T., Watanabe, T., Sobue, Y., Nishiume, T., Kato, M., Fujibayashi, T., Hirano, Y., Kanayama, Y., Takemoto, T., Watanabe, T., Hanabayashi, M., Matsubara, H., Suzuki, M., Takahashi, N., & Imagama, S. (2026). Comparative Analysis of the Effectiveness of Methotrexate Co-Administration with Baricitinib in Rheumatoid Arthritis Treatment. Modern Rheumatology. https://doi.org/10.1093/mr/roag099

Vancouver

Terabe K, Asai S, Yoshioka Y, Kato T, Kojima T, Kobayakawa T, et al. Comparative Analysis of the Effectiveness of Methotrexate Co-Administration with Baricitinib in Rheumatoid Arthritis Treatment. Modern Rheumatology. 2026. doi:10.1093/mr/roag099

BibTeX
@article{Terabe2026,
  author = {Terabe, Kenya and Asai, Shuji and Yoshioka, Yutaka and Kato, Takefumi and Kojima, Toshihisa and Kobayakawa, Tomonori and Watanabe, Tatsuo and Sobue, Yasumori and Nishiume, Tsuyoshi and Kato, Mihoko and Fujibayashi, Takayoshi and Hirano, Yuji and Kanayama, Yasuhide and Takemoto, Toki and Watanabe, Tsuyoshi and Hanabayashi, Masahiro and Matsubara, Hiroyuki and Suzuki, Mochihito and Takahashi, Nobunori and Imagama, Shiro},
  title = {Comparative Analysis of the Effectiveness of Methotrexate Co-Administration with Baricitinib in Rheumatoid Arthritis Treatment},
  journal = {Modern Rheumatology},
  year = {2026},
  doi = {10.1093/mr/roag099}
}
Kostenlos starten →